Anthony M Joshua

39PUBLICATIONS

337CO-AUTHORS

Predictive and prognostic markersPharmacogenomicsEpigenetics (incl. genome methylation and epigenomics)Cancer therapy (excl. chemotherapy and radiation therapy)Radiation therapy

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (39)

Sort by Publication Date:

|Jun 26, 2026

AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.

|Apr 28, 2026

<sup>177</sup>Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer.

|Apr 15, 2026

Predictive value of early PSMA upregulation for the response to enzalutamide ± <sup>177</sup>Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial.

|Mar 27, 2026

Challenging interpretation of low-level PTCH1 mosaicism in patients with clinically diagnosed Gorlin syndrome: a case series and review of the literature.

Tanya M Dwarte, Rozanna Alli, Shweta Srinivasa

|Mar 25, 2026

Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy-Naïve Localized Prostate Cancer.

Eva Apostolov, Daniel L Roden, Holly Holliday

|Mar 06, 2026

A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.

Barak Talmor, Stefano Marastoni, Brandon Lau

Pageof 7

Frequent Collaborators

Ian D Davis

Martin R Stockler

Hui-Ming Lin

Louise Emmett

Shahneen Sandhu

David R Croucher

Alexander W Wyatt

Bradly G Wouters

Edmond M Kwan

Megan Crumbaker

Frequent Collaborators

Ian D Davis

Martin R Stockler

Hui-Ming Lin

Louise Emmett